Pharmedium Recalls Subpotent Repinephrine Bitartrate Injection Bags
Pharmedium Services LLC is voluntarily recalling 5,820 bags of subpotent repinephrine bitartrate injection. The FDA classified this as a Class III recall.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Pharmedium Services LLC is voluntarily recalling 5,820 bags of NORepinephrine Bitartrate 8 mg added to 250 mL 5% Dextrose Injection USP. The product is a high-alert, prescription-only medication distributed nationwide in the United States. The recall was initiated because the drug was found to be subpotent, meaning it did not contain the full labeled amount of the active ingredient.
The FDA classified this recall as Class III, which indicates that use of or exposure to the violative product is not likely to cause adverse health consequences. The recall covers specific lots with expiration dates ranging from December 18, 2019, to January 30, 2020. The recall was initiated on December 16, 2019, and was terminated on February 9, 2021.
Healthcare providers and facilities that have received these products should stop using them and contact the recalling firm for instructions on return or disposal. Patients who have received this medication should consult their healthcare provider if they have questions about their treatment.
The recalled product
- Product
- NORepinephrine Bitartrate 8 mg added to 250 mL 5% Dextrose Injection USP (32 mcg per mL) Total Volume 258.00 mL Viaflex Bag, High Alert, Rx Only, PharMEDium Services LLC., 12620 W Airport Blvd #130 Sugar Land, TX 77478.
- Manufacturer
- Pharmedium Services, LLC
- Category
- Drug — Injection
- Hazard
- Affected units
- 5,820
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #s: 192930039S Exp. 12/18/19
- 192930041S Exp. 12/18/19
- 192940048S Exp. 12/19/19
- 192940049S Exp. 12/19/19
- 192950031S Exp. 12/20/19
- 192950032S Exp. 12/20/19
- 192960039S Exp. 12/22/19
- 192960040S Exp. 12/22/19
- 192960041S Exp. 12/22/19
- 192960042S Exp. 12/22/19
- 192970034S Exp. 12/22/19
- 192970036S Exp. 12/22/19
- 192970037S Exp. 12/22/19
- 192980043S Exp. 12/25/19
- 192980044S Exp. 12/25/19
- 192980045S Exp. 12/25/19
- 193010042S Exp. 12/26/19
- 193020042S Exp. 12/27/19
- 193030039S Exp. 12/28/19
- 193030040S Exp. 12/28/19
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Pharmedium Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Pharmedium Services, LLC
See all →- SeverePharMEDium Recalls ePHEDrine Sulfate Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls nICARdipine HCl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Rocuronium Bromide Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Rocuronium Bromide Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Fentanyl Citrate Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02